ENTX

Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

Where Might Entera Bio Stock End Up After Rallying Wednesday

ENTX Stock: The Huge FDA News Sending Entera Bio Soaring